Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections
- PMID: 27659435
- PMCID: PMC5048002
- DOI: 10.3947/ic.2016.48.3.209
Population Pharmacokinetic Analysis of Piperacillin/Tazobactam in Korean Patients with Acute Infections
Abstract
Background: For more effective and safer usage of antibiotics, the dosing strategy should be individualized based on the patients' characteristics, including race. The aim of this study was to investigate the population pharmacokinetic (PK) profiles of piperacillin and tazobactam in Korean patients with acute infections.
Materials and methods: At least four consecutive 2/0.25 g or 4/0.5 g doses of piperacillin/tazobactam (TZP) were intravenously infused over 1 h every 8 h for patients with creatinine clearance (CL(cr)) ≤50 ml/min or CL(cr) >50 mL/min, respectively. Blood samples from 33 patients at a steady-state were taken pre-dose and at 0 min, 30 min, and 4-6 h after the fourth infusion. The population PK analysis was conducted using a non-linear mixed-effects method. A likelihood ratio test was used to select significant covariates, with significance levels of P < 0.05 for selection and P < 0.01 for elimination.
Results: Both piperacillin PK and tazobactam PK were well described by a two-compartment model with first-order elimination. Creatinine clearance and body weight, as covariates on clearance (CL) and volume of central compartment (V1), were selected among the covariates possibly affecting PK parameters of both drugs. CL was defined as CL = 2.9 + 4.03 × CL(cr) /47 for piperacillin and CL = 1.76 + 4.81 × CL(cr) /47 for tazobactam. V1 was defined as V1 = 19.5 × weight/60 for piperacillin and V1 = 22.6 × weight/60 for tazobactam.
Conclusion: The PK profiles of TZP at a steady-state in Korean patients with acute infections were well described by a two-compartment model with first-order elimination. Both piperacillin and tazobactam clearances were significantly influenced by creatinine clearance.
Keywords: Clearance; Piperacillin; Population pharmacokinetics; Race; Tazobactam.
Conflict of interest statement
The study drug was provided by the Kuhnil Pharmaceutical Company.
Figures


Similar articles
-
Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children.Antimicrob Agents Chemother. 2019 Oct 22;63(11):e01260-19. doi: 10.1128/AAC.01260-19. Print 2019 Nov. Antimicrob Agents Chemother. 2019. PMID: 31427292 Free PMC article.
-
Pharmacokinetics of Piperacillin-Tazobactam in Critically Ill Patients with Open Abdomen and Vacuum-Assisted Wound Closure: Dosing Considerations Using Monte Carlo Simulation.Pharmaceutics. 2024 Sep 9;16(9):1191. doi: 10.3390/pharmaceutics16091191. Pharmaceutics. 2024. PMID: 39339227 Free PMC article.
-
Population pharmacokinetic analysis of piperacillin in burn patients.Antimicrob Agents Chemother. 2014 Jul;58(7):3744-51. doi: 10.1128/AAC.02089-13. Epub 2014 Apr 21. Antimicrob Agents Chemother. 2014. PMID: 24752260 Free PMC article.
-
Piperacillin-Tazobactam in Intensive Care Units: A Review of Population Pharmacokinetic Analyses.Clin Pharmacokinet. 2021 Jul;60(7):855-875. doi: 10.1007/s40262-021-01013-1. Epub 2021 Apr 20. Clin Pharmacokinet. 2021. PMID: 33876381 Review.
-
Pharmacokinetic evaluation of piperacillin-tazobactam.Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):1017-31. doi: 10.1517/17425255.2010.506187. Expert Opin Drug Metab Toxicol. 2010. PMID: 20636224 Review.
Cited by
-
Population pharmacokinetics and pharmacodynamics of piperacillin in critically ill patients during the early phase of sepsis.J Pharmacokinet Pharmacodyn. 2019 Jun;46(3):251-261. doi: 10.1007/s10928-019-09633-8. Epub 2019 Apr 8. J Pharmacokinet Pharmacodyn. 2019. PMID: 30963365
-
Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Simulation of Piperacillin/Tazobactam for Dosing Optimization in Late Elderly Patients with Pneumonia.Antibiotics (Basel). 2020 Mar 6;9(3):113. doi: 10.3390/antibiotics9030113. Antibiotics (Basel). 2020. PMID: 32155905 Free PMC article.
-
Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation.J Antimicrob Chemother. 2022 Apr 27;77(5):1353-1364. doi: 10.1093/jac/dkac059. J Antimicrob Chemother. 2022. PMID: 35224630 Free PMC article.
-
Scaling beta-lactam antimicrobial pharmacokinetics from early life to old age.Br J Clin Pharmacol. 2019 Feb;85(2):316-346. doi: 10.1111/bcp.13756. Epub 2018 Nov 26. Br J Clin Pharmacol. 2019. PMID: 30176176 Free PMC article.
-
Collaborative Pharmacokinetic-Pharmacodynamic Research for Optimization of Antimicrobial Therapy.Infect Chemother. 2016 Sep;48(3):254-256. doi: 10.3947/ic.2016.48.3.254. Infect Chemother. 2016. PMID: 27704737 Free PMC article. No abstract available.
References
-
- Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacilin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007;5:365–383. - PubMed
-
- Maltezou HC, Nikolaidis P, Lebesii E, Dimitriou L, Androulakakis E, Kafetzis DA. Piperacillin/tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis. 2001;20:643–646. - PubMed
-
- Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, Citton R, D’Inzeo T, Fadda G, Cauda R, Spanu T. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51:1987–1994. - PMC - PubMed
-
- Peralta G, Lamelo M, Alvarez-García P, Velasco M, Delgado A, Horcajada JP, Montero M, Roiz MP, Fariñas MC, Alonso J, Martínez LM, Gutiérrez-Macías A, Alava JA, Rodríguez A, Fleites A, Navarro V, Sirvent E, Capdevila JA, SEMI- BLEE STUDY GROUP Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp bacteremia. A multicentric cohort study. BMC Infect Dis. 2012;12:245. - PMC - PubMed
-
- Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis. 1998;27:10–22. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources